" class="no-js "lang="en-US"> Robert Rönn - Medtech Alert
Friday, September 26, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Robert Rönn

Robert Rönn

About Robert Rönn

Related Story

Clinical Trials

 Orexo’s Nasal Adrenaline Rescue Medication OX640 Enters Clinical Development | Pharmtech Focus

Orexo’s Nasal Adrenaline Rescue Medication OX640 Enters Clinical Development

July 5 2022

Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces it has successfully initiated the first explorative human clinical study […]

Drug Development

 Orexo Provides Information About its New Proprietary Drug Delivery Platform - AmorphOXTM | Pharmtech Focus

Orexo Provides Information About its New Proprietary Drug Delivery Platform - AmorphOXTM

November 26 2021

Orexo AB (publ.),(STO:ORX) (OTCQX:ORXOY) today provides information about its new proprietary drug delivery platform, amorphOXTM, a […]